Cited 1 time in
Bilateral ovarian granulocytic sarcoma as the primary manifestation of acute myelogenous leukemia treated with allogenic stem cell transplantation A case report
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Choi, Jung Yoon | - |
| dc.contributor.author | Kim, Hyun-Young | - |
| dc.contributor.author | Kang, Min Gyu | - |
| dc.contributor.author | Shin, Jeong Kyu | - |
| dc.contributor.author | Lee, Won Seop | - |
| dc.contributor.author | Song, Haa-Na | - |
| dc.date.accessioned | 2022-12-26T14:17:50Z | - |
| dc.date.available | 2022-12-26T14:17:50Z | - |
| dc.date.issued | 2019-12 | - |
| dc.identifier.issn | 0025-7974 | - |
| dc.identifier.issn | 1536-5964 | - |
| dc.identifier.uri | https://scholarworks.gnu.ac.kr/handle/sw.gnu/8488 | - |
| dc.description.abstract | Rationale: Granulocytic sarcoma (GS), also known as chloroma, is a tumor comprising myeloblasts or monoblasts, potentially occurring as an extramedullary mass. Systemic chemotherapy should be used to induce complete remission. However, such patients with chloroma have a poorer treatment outcome than those without extramedullary myeloid sarcomas. Patient concerns: A 30-year-old woman who initially presented with bilateral ovarian masses and splenomegaly was admitted to hospital. Also, her complete blood cell counts showed pancytopenia and blood smear revealed a few immature cells (3%). Diagnoses: A bone marrow biopsy demonstrated acute myelomonocytic leukemia, and the chromosomal analysis revealed a 46, XX, del18 (p11) [20] karyotype and cytogenetics and molecular markers showed all negative results. Interventions: Since this diagnosis, she received remission-inducing chemotherapy comprising anthracycline and cytarabine, which is a standard regimen for acute myeloid leukemia (AML), and followed by allogenic hematopoietic stem cell transplantation from Human leukocyte antigen (HLA)-identical sibling donor. Outcomes: After transplantation, the bone marrow engrafted successfully without complications. She visited our clinic regularly with no evidence of leukemia relapse or graft-versus host disease. Lessons: This report represents the first case of ovarian GS, wherein treatment was successful with high-dose chemotherapy, followed by allogenic hematopoietic stem cell transplantation without oophorectomy. | - |
| dc.language | 영어 | - |
| dc.language.iso | ENG | - |
| dc.publisher | Lippincott Williams & Wilkins Ltd. | - |
| dc.title | Bilateral ovarian granulocytic sarcoma as the primary manifestation of acute myelogenous leukemia treated with allogenic stem cell transplantation A case report | - |
| dc.type | Article | - |
| dc.publisher.location | 미국 | - |
| dc.identifier.doi | 10.1097/MD.0000000000018390 | - |
| dc.identifier.scopusid | 2-s2.0-85077184286 | - |
| dc.identifier.wosid | 000512890300009 | - |
| dc.identifier.bibliographicCitation | Medicine, v.98, no.52 | - |
| dc.citation.title | Medicine | - |
| dc.citation.volume | 98 | - |
| dc.citation.number | 52 | - |
| dc.type.docType | Article | - |
| dc.description.isOpenAccess | Y | - |
| dc.description.journalRegisteredClass | sci | - |
| dc.description.journalRegisteredClass | scie | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.relation.journalResearchArea | General & Internal Medicine | - |
| dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
| dc.subject.keywordAuthor | acute myeloid leukaemia | - |
| dc.subject.keywordAuthor | granulocytic sarcoma | - |
| dc.subject.keywordAuthor | stem cell transplantation | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
Gyeongsang National University Central Library, 501, Jinju-daero, Jinju-si, Gyeongsangnam-do, 52828, Republic of Korea+82-55-772-0534
COPYRIGHT 2022 GYEONGSANG NATIONAL UNIVERSITY LIBRARY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
